Few clues to flotation fever in past performance
Investors are piling into biotech IPOs, but the track record of previous years' new issues shows how hard it is to pick winners.
China comes of age
Chi-Med is not alone in seeing Chinese approval as the prelude to a regulatory green light in the west.
Another huge quarter for biotech flotations
Another billion dollar quarter for biotech IPOs signals that investor appetite for high-risk offerings is strong.
